REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal definition of a rare disease and no universal approach to orphan drugs legislation. As a result, decision-making in this field requires results of pharmacoeconomic analysis, which structure and interpretatio...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2015-09-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/98 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849249665890910208 |
|---|---|
| author | Andrey Vladislavovich Pavlysh Aleksei Sergeevich Kolbin Roman Andreevich Gapeshin Stanislav Mikhailovich Malyshev |
| author_facet | Andrey Vladislavovich Pavlysh Aleksei Sergeevich Kolbin Roman Andreevich Gapeshin Stanislav Mikhailovich Malyshev |
| author_sort | Andrey Vladislavovich Pavlysh |
| collection | DOAJ |
| description | Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal definition of a rare disease and no universal approach to orphan drugs legislation. As a result, decision-making in this field requires results of pharmacoeconomic analysis, which structure and interpretation need a specific approach due to high costs of the drugs and limited sample size. Cost-utility analysis, risk management, and international rare diseases patient registries could be used to solve these problems. |
| format | Article |
| id | doaj-art-0e6d3309dce7495b86dcf8a886b63afb |
| institution | Kabale University |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2015-09-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-0e6d3309dce7495b86dcf8a886b63afb2025-08-20T03:57:30ZrusIRBIS LLCФармакоэкономика2070-49092070-49332015-09-018231010.17749/2070-4909.2015.8.2.003-01088REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONSAndrey Vladislavovich Pavlysh0Aleksei Sergeevich Kolbin1Roman Andreevich Gapeshin2Stanislav Mikhailovich Malyshev3First St. Petersburg State Medical University; The Federal State Budgetary Institute «The Nikiforov Russian Center of Emergency and Radiation Medicine» The Ministry of Russian Federation for Civil Defense, Emergencies and Elimination of Consequences of Natural DisastersFirst St. Petersburg State Medical University; First St. Petersburg State UniversitySt. Petersburg State UniversitySt. Petersburg State UniversityOrphan drugs are used for treatment of rare life-threatening diseases. There is no universal definition of a rare disease and no universal approach to orphan drugs legislation. As a result, decision-making in this field requires results of pharmacoeconomic analysis, which structure and interpretation need a specific approach due to high costs of the drugs and limited sample size. Cost-utility analysis, risk management, and international rare diseases patient registries could be used to solve these problems.https://www.pharmacoeconomics.ru/jour/article/view/98pharmacoeconomicsorphan drugsrare diseasescost-utility analysis |
| spellingShingle | Andrey Vladislavovich Pavlysh Aleksei Sergeevich Kolbin Roman Andreevich Gapeshin Stanislav Mikhailovich Malyshev REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS Фармакоэкономика pharmacoeconomics orphan drugs rare diseases cost-utility analysis |
| title | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS |
| title_full | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS |
| title_fullStr | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS |
| title_full_unstemmed | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS |
| title_short | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS |
| title_sort | reasons for difficulty of the pharmacoeconomic analysis for orphan drugs ways for solutions |
| topic | pharmacoeconomics orphan drugs rare diseases cost-utility analysis |
| url | https://www.pharmacoeconomics.ru/jour/article/view/98 |
| work_keys_str_mv | AT andreyvladislavovichpavlysh reasonsfordifficultyofthepharmacoeconomicanalysisfororphandrugswaysforsolutions AT alekseisergeevichkolbin reasonsfordifficultyofthepharmacoeconomicanalysisfororphandrugswaysforsolutions AT romanandreevichgapeshin reasonsfordifficultyofthepharmacoeconomicanalysisfororphandrugswaysforsolutions AT stanislavmikhailovichmalyshev reasonsfordifficultyofthepharmacoeconomicanalysisfororphandrugswaysforsolutions |